Olema Pharmaceuticals Inc.
OLMA
Olema is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for breast cancer and beyond. We are advancing our pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$236M
▼ -25.5% YoY
Op. Margin
–
ROIC
-45.34%
▲ +2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$177M
▼ -40.4% YoY
Op. Cash Flow (TTM)
-$177M
▼ -40.6% YoY
Net Debt
-$413M
Net Cash Position
Cash & Equiv.
$414M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with OLMA
Held by ETFs
OLMA is in 29 US ETFs. The largest of them, with OLMA's weight in each:
Olema Pharmaceuticals (OLMA) in two numbers
Questions about Olema Pharmaceuticals
Does Olema Pharmaceuticals (OLMA) pay a dividend?
No. Olema Pharmaceuticals (OLMA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 6 Aug 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in OLMA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing OLMA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.